Buy This Dip in Orexigen (OREX), RBC Capital Says
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P 500 inches lower as Middle East tensions outweigh tech gains
- L3Harris CEO steps down amid conduct review, shares drop
- Reddit leads social media platforms in revenue growth per user
- Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
Orexigen (OREX) Comments on Light Study Termination; Takeda Initiated Formal Dispute Process
May 13, 2015 6:05 AM EDTOrexigen Therapeutics (NASDAQ: OREX) issued the following statement regarding the termination of the Light Study a cardiovascular (CV) outcomes trial that compared the obesity drug Contrave® (naltrexone HCI and bupropion HCl extended-release tablets) to placebo, in addition to diet and exercise counselling, in 8,909 overweight and obese patients with certain CV risk factors, and an update on its Contrave collaboration with Takeda Pharmaceuticals Company.
This morning (Tuesday morning) we and Takeda announced termination of the Light Study. We agreed with our partner, and together discussed our preferences with the U.S. Food and... More
UPDATE: Orexigen Therapeutics (OREX) and Takeda in Arbitration Over Terms of Deal
May 12, 2015 4:25 PM EDT(Updated - May 12, 2015 4:27 PM EDT)
Orexigen Therapeutics (NASDAQ: OREX) and Takeda are in arbitration on terms of collaboration, the company's CEO says in Bank of America presentation, according to CNBC's Meg Tirrell.
... More
Orexigen Therapeutics (OREX) Defended at Leerink
May 12, 2015 1:52 PM EDTOrexigen Therapeutics (NASDAQ: OREX) was defended a Leerink amid controversy after the company's Light trial was halted. Comments follow criticism in Forbes, which may have triggered a sell-off in the stock. In the view of analyst Paul Matteis, Light data showed what was expected -- safety and a positive trend.
"After OREX and Takeda announced the termination of the LIGHT study this morning, a Forbes article just disclosed data from the 50% interim analysis of the LIGHT study. Consistent with our... More
Orexigen Therapeutics (OREX) Mentioned Cautiously at Forbes
May 12, 2015 11:20 AM EDTOrexigen Therapeutics (NASDAQ: OREX) was mentioned cautiously in a Forbes article discussing results of its Light study of Contrave (link here).
... MoreLight Study Termination 'Positive' for Orexigen (OREX), Leerink Partners Says
May 12, 2015 9:51 AM EDTLeerink Partners Paul Matteis said the termination of the Light Study by Orexigen Therapeutics (NASDAQ: OREX) and partner Takeda is a "positive."
"The stopping of the study is not due to any finding of superiority or harm. We believe the termination... More
Takeda, Orexigen Therapeutics (OREX) Announce Early Termination of Light Study
May 12, 2015 8:34 AM EDTTakeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Development Center Americas, Inc. (Takeda) and Orexigen Therapeutics, Inc. (Nasdaq: OREX) (Orexigen) have accepted the recommendation of the Executive Steering Committee (ESC), chaired by Dr. Steven Nissen of The Cleveland Clinic, for early termination of the Light Study, a... More
